NCT01839019已完成1 期
Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Safety measures, i.e. assessing adverse events, vital signs, ECG and safety laboratory values
研究概览
简要总结
The purpose of the study is to evaluate the safety and tolerability of escalating single doses of ODM-102 in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written informed consent (IC) obtained.
- •Good general health ascertained by detailed medical history and physical examination.
- •Finnish-speaking males between 18 and 45 years of age (inclusive).
- •Body mass index (BMI) between 18.0-30.5 kg/m2 (inclusive).
- •Weight 55.0-100.0 kg (inclusive).
排除标准
- •Suspected poor compliance or inability to communicate well with the investigator.
- •Veins unsuitable for repeated venipuncture.
- •Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.
- •Any condition requiring regular concomitant drug treatment, including herbal products, or likely to need any concomitant drug treatment during the study.
- •Susceptibility to severe allergic reactions.
- •Intake of any medication that could affect the outcome of the study within 2 weeks prior to the first study drug administration or within less than 5 times the elimination half-life of the medication.
- •Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits, about 13 g of alcohol).
- •Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.
- •Inability to refrain from using nicotine-containing products during the stay in the study centre.
- •Inability to refrain from consuming caffeine-containing beverages during the first 24 hours after treatment administration e.g. propensity to experience headache when abstaining from caffeine-containing beverages.
- •Blood donation or loss of a significant amount of blood within 2 months prior to the screening visit.
- •Abnormal 12-lead ECG finding of clinical relevance after 10 min rest in supine position at the screening visit
- •HR < 45 beats/minute or > 90 beats/minute after 10 minutes rest in supine position at the screening visit.
- •At the screening visit, systolic BP < 90 mmHg or > 140 mmHg after 10 minutes in supine position, diastolic BP < 50 mmHg or > 90 mmHg after 10 minutes in supine position, or symptomatic orthostatic hypotension, or decrease of ≥ 20 mmHg of systolic BP or decrease of ≥ 10 mmHg of diastolic BP after 3 minutes in standing position.
- •Abnormal 24-hour Holter ECG recording of possible or confirmed clinical relevance
- •Any abnormal laboratory value, vital sign, or physical examination finding, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk to the subject if he takes part in the study.
- •Suspected current use of illicit drugs (according to medical history enquiry or physical examination), positive drug screen or history of long-term drug abuse.
- •Positive serology to human immunodeficiency virus antigen/antibodies (HIVAgAb), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus antibodies (HCVAb).
- •Participation in another clinical drug study within 3 months prior to the first treatment administration in this study.
- •Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
研究组 & 干预措施
Placebo
Placebo Comparator
Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
干预措施: Placebo for ODM-102 (Drug)
ODM-102
Experimental
Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
干预措施: ODM-102 (Drug)
结局指标
主要结局
Safety measures, i.e. assessing adverse events, vital signs, ECG and safety laboratory values
时间窗: about a month
次要结局
- Pharmacokinetics(5 days per period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy SubjectsTumorsBreast CancerLeukemiaNCT00777530Wyeth is now a wholly owned subsidiary of Pfizer48
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male VolunteersHealthyNCT02183545Boehringer Ingelheim80
已完成
1 期
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without FoodHealthyNCT04801693Boehringer Ingelheim66
终止
1 期
Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy SubjectsHealthyNCT03195088Boehringer Ingelheim16
已完成
1 期
Study Evaluating The SBI-087 In Subjects With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT00714116Pfizer30